Retatrutide and Heart Health (Cardiovascular Effects)
Cardiovascular disease is the leading cause of death globally, and obesity is one of its most significant modifiable risk factors. The GLP-1 drug class has changed the conversation about obesity treatment by demonstrating not just weight loss, but direct cardiovascular risk reduction — semaglutide's landmark SELECT trial showed a 20% reduction in major adverse cardiovascular events (MACE) in people with obesity and established cardiovascular disease.
Retatrutide's cardiovascular story is still early. No dedicated cardiovascular outcomes data has been published yet. However, the data we do have — from the TRIUMPH-4 Phase 3 trial and Phase 2 studies — shows consistent improvements in blood pressure, lipids, and inflammatory markers. Two large trials (TRIUMPH-3 and TRIUMPH-Outcomes) are specifically designed to evaluate retatrutide's cardiovascular effects.
Retatrutide is an investigational drug that has not been approved by the FDA.
What We Know So Far
TRIUMPH-4 Cardiovascular Markers
The TRIUMPH-4 trial (NCT05931367), while designed primarily for obesity and knee osteoarthritis, reported several cardiometabolic outcomes:
| Marker | 12mg Result | Clinical Significance |
|---|---|---|
| Systolic blood pressure | -14.0 mmHg | Comparable to some antihypertensive drugs |
| Non-HDL cholesterol | Improved | Key predictor of atherosclerotic cardiovascular risk |
| hsCRP | Improved | Marker of systemic inflammation linked to CV events |
| Triglycerides | Improved | Elevated triglycerides are an independent CV risk factor |
Source: Eli Lilly TRIUMPH-4 press release, December 2025
Blood pressure reduction
The 14.0 mmHg reduction in systolic blood pressure at the 12mg dose is clinically meaningful. For context:
- A 10 mmHg reduction in systolic blood pressure is associated with a ~20% reduction in major cardiovascular events and a ~13% reduction in all-cause mortality
- The effect size seen with retatrutide is comparable to what some first-line antihypertensive medications achieve
- This blood pressure reduction is likely driven by both weight loss and direct metabolic effects of the drug
Phase 2 data
The Phase 2 trials in both obesity (NCT04881760) and type 2 diabetes (NCT04867785) also showed improvements in:
- Blood pressure
- Lipid profiles (cholesterol, triglycerides)
- Insulin sensitivity
- Markers of metabolic syndrome
These findings are consistent across dose levels and populations, providing a coherent signal that retatrutide produces broad cardiometabolic improvement.
The Cardiovascular Trials
TRIUMPH-3: Obesity in Cardiovascular Disease Population
| Detail | Value |
|---|---|
| Indication | Weight management in people with cardiovascular disease |
| Phase | 3 |
| Status | Active — results expected 2026 |
TRIUMPH-3 evaluates retatrutide specifically in people with obesity who also have established cardiovascular disease. This population is at the highest risk and represents the group where cardiovascular benefits (or risks) would be most apparent. The trial will provide critical data on retatrutide's safety and efficacy in a CV-risk population.
TRIUMPH-Outcomes (TRIUMPH-5): The Cardiovascular and Kidney Outcomes Trial
| Detail | Value |
|---|---|
| Full name | TRIUMPH-Outcomes (also referred to as TRIUMPH-5) |
| Population | Adults with BMI ≥27 + atherosclerotic cardiovascular disease and/or chronic kidney disease |
| Duration | ~5 years |
| Primary endpoint | Major adverse cardiovascular events (MACE) and kidney outcomes |
| Phase | 3 |
| Status | Recruiting / active |
This is the definitive cardiovascular and renal outcomes trial for retatrutide. It is designed to answer the fundamental question: does retatrutide reduce the risk of heart attacks, strokes, cardiovascular death, and kidney disease progression?
TRIUMPH-Outcomes follows the model established by semaglutide's SELECT trial and follows the pattern now expected by regulators, insurers, and the medical community for GLP-1 class drugs.
Why outcomes trials matter
Improving surrogate markers (blood pressure, cholesterol, inflammatory markers) is encouraging but does not prove a drug reduces actual cardiovascular events. That requires a large, long-term trial measuring hard clinical endpoints — heart attacks, strokes, and death. These trials typically:
- Enroll thousands of participants
- Run for several years
- Are expensive and logistically complex
- Provide the highest level of clinical evidence
A positive TRIUMPH-Outcomes result would be transformative for retatrutide's clinical and commercial positioning, potentially leading to a cardiovascular indication similar to what Wegovy received after the SELECT trial.
How Retatrutide's Mechanism Relates to Heart Health
GLP-1 receptor
GLP-1 receptor agonism has demonstrated direct cardiovascular benefits independent of weight loss. Potential mechanisms include:
- Reduced arterial inflammation — GLP-1 receptors are present in the vasculature, and activation reduces inflammatory processes in blood vessel walls
- Improved endothelial function — the lining of blood vessels functions better, reducing atherosclerosis progression
- Reduced platelet aggregation — potentially lowering clot formation risk
GIP receptor
The cardiovascular effects of GIP receptor agonism are less well characterized. GIP receptors are present in the heart and vasculature, but their role in cardiovascular health is an active area of research. Tirzepatide (which includes GIP agonism) has shown cardiovascular safety, and its own cardiovascular outcomes trial (SURPASS-CVOT) is ongoing.
Glucagon receptor
Retatrutide's glucagon component may contribute cardiovascular benefits through:
- Enhanced lipid metabolism — glucagon promotes hepatic fatty acid oxidation, which can improve lipid profiles
- Reduced liver fat — MASLD/MASH is associated with increased cardiovascular risk, and retatrutide has shown dramatic liver fat reductions (see Retatrutide and Fatty Liver Disease)
- Increased energy expenditure — beyond weight loss, the shift in metabolic activity may have independent cardiovascular effects
- Potential blood pressure effects — through improved metabolic health and reduced sympathetic nervous system activation
The combination of all three receptors may produce cardiovascular benefits greater than any single receptor alone, though this hypothesis requires confirmation from outcomes data.
The GLP-1 Cardiovascular Landscape
Retatrutide enters a landscape where cardiovascular benefit has become a key differentiator for GLP-1 class drugs:
| Drug | CV Outcomes Trial | Result | Status |
|---|---|---|---|
| Semaglutide (Wegovy) | SELECT | 20% MACE reduction | Completed — approved for CV risk reduction |
| Tirzepatide (Zepbound) | SURPASS-CVOT | Pending | Ongoing |
| Retatrutide | TRIUMPH-Outcomes | Pending | Recruiting / active |
Semaglutide's SELECT trial changed the field by demonstrating that a weight loss drug could directly reduce cardiovascular events. This has raised the bar — payers (insurers) increasingly require cardiovascular outcomes data before providing broad coverage for obesity drugs. For retatrutide, a positive TRIUMPH-Outcomes trial could be the difference between a niche weight loss drug and a broadly covered cardiometabolic therapy.
What We Do Not Know Yet
Several important cardiovascular questions remain unanswered for retatrutide:
- Hard outcomes: We do not know whether retatrutide reduces heart attacks, strokes, or cardiovascular death. Only TRIUMPH-Outcomes can answer this, and results are years away.
- Comparative benefit: We do not know whether retatrutide offers greater cardiovascular protection than semaglutide or tirzepatide. No head-to-head cardiovascular outcomes trial is planned.
- Glucagon's net cardiovascular effect: While glucagon agonism has theoretical cardiovascular benefits, it also increases heart rate in some studies. The net cardiovascular effect of adding glucagon to GLP-1/GIP is not yet characterized in long-term data.
- Arrhythmia risk: Weight loss drugs and glucagon-related compounds can affect heart rate and rhythm. Long-term arrhythmia data is not yet available.
- Kidney outcomes: TRIUMPH-Outcomes includes kidney endpoints, but renal data has not been published for retatrutide.
Frequently Asked Questions
Does retatrutide reduce cardiovascular risk?
We do not yet know. Early data shows improvements in blood pressure, cholesterol, triglycerides, and inflammatory markers — all of which are associated with reduced cardiovascular risk. However, proving actual risk reduction requires a dedicated cardiovascular outcomes trial (TRIUMPH-Outcomes), which is ongoing and will take several years to complete.
How does retatrutide's blood pressure reduction compare to blood pressure medications?
The 14.0 mmHg systolic blood pressure reduction seen at the 12mg dose in TRIUMPH-4 is comparable to the effect of some first-line antihypertensive drugs (ACE inhibitors, ARBs, and thiazide diuretics typically reduce SBP by 8-15 mmHg). However, retatrutide is not a blood pressure medication — this is a secondary effect of the drug's weight loss and metabolic activity.
Should I take retatrutide for heart health?
Retatrutide is not approved for any indication, including cardiovascular risk reduction. If you have cardiovascular risk factors or established heart disease, work with your cardiologist on a treatment plan using proven therapies. Semaglutide (Wegovy) is currently the only GLP-1 drug with an FDA-approved cardiovascular risk reduction indication, based on the SELECT trial.
Will retatrutide replace heart medications?
No. Even if TRIUMPH-Outcomes shows cardiovascular benefit, retatrutide would likely be used in addition to, not instead of, established cardiovascular medications such as statins, antihypertensives, and antiplatelet agents. The GLP-1 class is being positioned as an added layer of cardiometabolic protection, not a replacement for existing standard of care.
Sources
- Eli Lilly and Company. (2025). Lilly's retatrutide achieved significant weight loss and pain relief in adults with obesity and knee osteoarthritis. Press release.
- Lincoff, A.M., et al. (2023). Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). New England Journal of Medicine. DOI: 10.1056/NEJMoa2307563
- Jastreboff, A.M., et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine. DOI: 10.1056/NEJMoa2301972
- ClinicalTrials.gov: NCT05931367, Retatrutide trials
Medical Disclaimer
The content on glp3.wiki is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Retatrutide is an investigational drug that has not been approved by the U.S. Food and Drug Administration (FDA) or any other regulatory agency.
If you have cardiovascular disease or cardiovascular risk factors, do not delay or change your current treatment based on information about an unapproved drug. Work with your cardiologist or primary care physician to manage your cardiovascular health using proven, approved therapies.
This site is not affiliated with Eli Lilly and Company or any pharmaceutical manufacturer.
Sources
- TRIUMPH-4 press release
Eli Lilly
- SELECT trial (semaglutide CV outcomes)
NEJM
- All retatrutide trials
ClinicalTrials.gov
Related reading
Retatrutide Clinical Trials & Results
Living tracker of all retatrutide trials — Phase 1 through the TRIUMPH Phase 3 program.
Retatrutide Side Effects & Safety
Clinical trial safety data, the new dysesthesia signal, and how side effects compare to existing GLP-1 drugs.
What Is Retatrutide (GLP-3)?
The world's first triple agonist weight loss drug — how it works, what the trials show, and why people call it GLP-3.